REFERENCES
1. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. Int J Mol Sci. 2019;20:1820.
2. Fan X, Zhang Z, Zheng L, Wei W, Chen Z. Long non-coding RNAs in the pathogenesis of heart failure: a literature review. Front. Cardiovasc. Med. 2022;9:950284.
4. Sato Y, Yoshihisa A, Takeishi Y. Organ injury and its management in heart failure: liver, kidney, and thyroid gland dysfunction. Fukushima J Med Sci. 2024;70:111-7.
5. Beghini A, Sammartino AM, Papp Z, et al. 2024 update in heart failure. ESC Heart Failure. 2025;12:8-42.
6. Heidenreich P. Heart failure management guidelines: new recommendations and implementation. J Cardiol. 2024;83:67-73.
7. Oremek GM, Passek K, Holzgreve F, Von Der Eltz V, Dröge J. Die biomarker BNP und NTproBNP. Zbl Arbeitsmed. 2023;73:89-95.
8. Jha S, Thasma Loganathbabu VK, Kumaran K, Krishnasamy G, Aruljothi KN. Long non-coding RNAs (lncRNAs) in heart failure: a comprehensive review. ncRNA. 2023;10:3.
9. Dhanoa JK, Sethi RS, Verma R, Arora JS, Mukhopadhyay CS. Long non-coding RNA: its evolutionary relics and biological implications in mammals: a review. J Anim Sci Technol. 2018;60:25.
10. Hinderer S, Schenke-layland K. Cardiac fibrosis - a short review of causes and therapeutic strategies. Adv Drug Delivery Rev. 2019;146:77-82.
11. Xuan L, Sun L, Zhang Y, et al. Circulating long non‐coding RNAs NRON and MHRT as novel predictive biomarkers of heart failure. J Cell Mol Med. 2017;21:1803-14.
12. Gao H, Yang S, Gao J, et al. An experimental study to estimate the early postmortem interval based on the degradation of lncRNAs in rat brain tissue. Sci Rep. 2024;14:19586.
13. Zhao J, Huang H. Extracellular vesicle-derived non-coding RNAs: key mediators in remodelling heart failure. Curr Issues Mol Biol. 2024;46:9430-48.
14. Gargiulo P, Marzano F, Salvatore M, et al. MicroRNAs: diagnostic, prognostic and therapeutic role in heart failure-a review. ESC Heart Failure. 2023;10:753-61.
15. Yan H, Ma F, Zhang Y, et al. miRNAs as biomarkers for diagnosis of heart failure: a systematic review and meta-analysis. Medicine. 2017;96:e6825.
16. Balion C, Santaguida PL, Hill S, et al. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. Evid Rep Technol Assess. 2006;142:1-147.
17. Profire B, Lupașcu FG, Stătescu C, et al. Heart failure biomarkers-pathophysiology, diagnosis, prognosis and clinical relevance. Int J Mol Sci. 2025;26:9740.
18. Kim S, Jang S, Lee S, Park J, Lee S, Kim H. Characterization of exosomes and exosomal RNAs isolated from post-mortem body fluids for molecular forensic diagnosis. Diagnostics. 2022;12:2153.
19. McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2023;44:3627-39.
20. Greco S, Zaccagnini G, Perfetti A, et al. Long noncoding RNA dysregulation in ischemic heart failure. J Transl Med. 2016;14:183.
21. Han P, Li W, Lin C, et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature. 2014;514:102-6.
22. Ge Z, Yin C, Li Y, et al. Long noncoding RNA NEAT1 promotes cardiac fibrosis in heart failure through increased recruitment of EZH2 to the Smad7 promoter region. J Transl Med. 2022;20:7.
23. Yu Q, Li Y, Zhang N, et al. Silencing of lncRNA NEAT1 alleviates acute myocardial infarction by suppressing miR-450-5p/ACSL4-mediated ferroptosis. Exp Cell Res. 2024;442:114217.
24. Yan L, Zhang Y, Wang M, Wang L, Zhang W, Ge Z. Circulating LIPCAR is a potential biomarker of heart failure in patients post-acute myocardial infarction. Exp Biol Med. 2021;246:2589-94.
25. Turkieh A, Beseme O, Saura O, et al. LIPCAR levels in plasma-derived extracellular vesicles is associated with left ventricle remodeling post-myocardial infarction. J Transl Med. 2024;22:31.
26. Yang Y, Mbikyo MB, Zhang J, Zhang Y, Zhang N, Li Z. The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through m6A RNA methylation reading protein Ythdf2. Cell Death Discov. 2022;8:167.
27. Zhang Y, Jiao L, Sun L, et al. LncRNAZFAS1 as a SERCA2a inhibitor to cause intracellular Ca2+ overload and contractile dysfunction in a mouse model of myocardial infarction. Circ Res. 2018;122:1354-68.
28. Su W, Huo Q, Wu H, et al. The function of LncRNA-H19 in cardiac hypertrophy. Cell Biosci. 2021;11:153.
29. Choong OK, Chen C, Zhang J, et al. Hypoxia-induced H19/YB-1 cascade modulates cardiac remodeling after infarction. Theranostics. 2019;9:6550-67.
30. Li J, Chen Z, Wang X, Song H. LncRNA UCA1, miR‐26a, and miR‐195 in coronary heart disease patients: correlation with stenosis degree, cholesterol levels, inflammatory cytokines, and cell adhesion molecules. J Clin Lab Anal. 2021;36:e24070.
31. Li X, Dai Y, Yan S, et al. Down-regulation of lncRNA KCNQ1OT1 protects against myocardial ischemia/reperfusion injury following acute myocardial infarction. Biochem Biophys Res Commun. 2017;491:1026-33.
32. Brunello E, Fusi L, Ghisleni A, et al. Myosin filament-based regulation of the dynamics of contraction in heart muscle. Proc. Natl. Acad. Sci. U.S.A. 2020;117:8177-86.
34. Zhang Y, Yao X-H, Wu Y, Cao G-K, Han D. LncRNA NEAT1 regulates pulmonary fibrosis through miR-9-5p and TGF-β signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24:8483-92.
35. Shu L, Zhang W, Huang C, Huang G, Su G, Xu J. lncRNA ANRIL protects H9c2 cells against hypoxia‐induced injury through targeting the miR‐7‐5p/SIRT1 axis. J Cell Physiol. 2019;235:1175-83.
37. Hinton A, Claypool SM, Neikirk K, et al. Mitochondrial structure and function in human heart failure. Circ Res. 2024;135:372-96.
38. Kamradt ML, Makarewich CA. CHKB-DT: A long noncoding RNA critical for cardiovascular health. Circ Res. 2024;134:442-4.
39. Eisner DA, Caldwell JL, Kistamás K, Trafford AW. Calcium and excitation-contraction coupling in the heart. Circ Res. 2017;121:181-95.
40. Jiang D, Wang J, Wang R, Wu Y. Comprehensive insights into mechanisms for ventricular remodeling in right heart failure. Rev Cardiovasc Med. 2024;25:426.
41. Khan S, Joyce J, Margulies KB, Tsuda T. Enhanced bioactive myocardial transforming growth factor-β in advanced human heart failure. Circ J. 2014;78:2711-8.
42. Li X, Wang H, Yao B, Xu W, Chen J, Zhou X. lncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy. Sci Rep. 2016;6:36340.
43. Wang Z, Zhang X, Ji Y, et al. The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat Med. 2016;22:1131-9.
44. Viereck J, Kumarswamy R, Foinquinos A, et al. Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med. 2016;8.
45. Van Heesch S, Witte F, Schneider-lunitz V, et al. The translational landscape of the human heart. Cell. 2019;178:242-260.e29.
46. Yan Y, Tang R, Li B, et al. The cardiac translational landscape reveals that micropeptides are new players involved in cardiomyocyte hypertrophy. Mol Ther. 2021;29:2253-67.
47. Barbalata T, Niculescu LS, Stancu CS, Pinet F, Sima AV. Elevated levels of circulating lncRNAs LIPCAR and MALAT1 predict an unfavorable outcome in acute coronary syndrome patients. Int J Mol Sci. 2023;24:12076.
48. Qi X, Yu L, Liu S, et al. The expression profile analysis and functional prediction of lncRNAs in peripheral blood mononuclear cells in maintenance hemodialysis patients developing heart failure. Sci Rep. 2024;14:29577.
49. Ma Y, Brocchini S, Williams GR. Extracellular vesicle-embedded materials. J Control Release. 2023;361:280-96.
50. Willms E, Johansson HJ, Mäger I, et al. Cells release subpopulations of exosomes with distinct molecular and biological properties. Sci Rep. 2016;6:22519.
51. Berumen Sánchez G, Bunn KE, Pua HH, Rafat M. Extracellular vesicles: mediators of intercellular communication in tissue injury and disease. Cell Commun Signal. 2021;19:104.
52. Gezer U, Özgür E, Cetinkaya M, Isin M, Dalay N. Long non‐coding RNAs with low expression levels in cells are enriched in secreted exosomes. Cell Biol Int. 2014;38:1076-9.
53. Kim KM, Abdelmohsen K, Mustapic M, Kapogiannis D, Gorospe M. RNA in extracellular vesicles. WIREs RNA. 2017;8:e1413.
54. Wang L, Zhang Y, Wang J, et al. Exosomal lncRNA profiles in patients with HFrEF: evidence for KLF3-AS1 as a novel diagnostic biomarker. Mol Cell Probes. 2025;82:102032.
55. Li J, Wu X, Ma H, et al. New developments in non-exosomal and exosomal ncRNAs in coronary artery disease. Epigenomics. 2022;14:1355-72.
56. Zhao L, Gu M, Sun Z, et al. The role of exosomal lncRNAs in cardiovascular disease: emerging insights based on molecular mechanisms and therapeutic target level. Non-coding RNA Res. 2025;10:198-205.
57. Liu Y, Wang C, Fu X, Ren M. The progress and evolving trends in nucleic-acid-based therapies. Biomolecules. 2025;15:376.
58. Kim Y. RNA therapy: rich history, various applications and unlimited future prospects. Exp Mol Med. 2022;54:455-65.
59. Michalik KM, You X, Manavski Y, et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res. 2014;114:1389-97.
60. Deiman FE, De Graaf MM, Sillje HHW, Grote Beverborg N, Bomer N, Van Der Meer P. RNA therapeutics in heart failure. J Cardiovasc Transl Res. 2025;18:1540-54.
61. Li Y, Wang Z, Ishmael D, Lvy Y. The potential of using non-coding RNAs in forensic science applications. Forensic Sci Res. 2023;8:98-106.
62. Hanson EK, Lubenow H, Ballantyne J. Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs. Anal Biochem. 2009;387:303-14.
63. Hiyamizu S, Ishida Y, Yasuda H, et al. Forensic significance of intracardiac expressions of Nrf2 in acute myocardial ischemia. Sci Rep. 2024;14:4046.
64. Frangogiannis NG. The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Investig. 2017;127:1600-12.
65. Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164:1226-32.
66. Chistiakov D, Orekhov A, Bobryshev Y. Cardiac extracellular vesicles in normal and infarcted heart. Int J Mol Sci. 2016;17:63.
67. Wang L, Zhang J. Exosomal lncRNA AK139128 derived from hypoxic cardiomyocytes promotes apoptosis and inhibits cell proliferation in cardiac fibroblasts. Int J Nanomedicine. 2020;15:3363-76.
68. Bellin G, Gardin C, Ferroni L, et al. Exosome in cardiovascular diseases: a complex world full of hope. Cells. 2019;8:166.
69. Bernáth-nagy D, Kalinyaprak MS, Giannitsis E, et al. Circulating extracellular vesicles as biomarkers in the diagnosis, prognosis and therapy of cardiovascular diseases. Front. Cardiovasc. Med. 2024;11:1425159.
